ARCHIVES

NSABP Accrual Slow, But Auditing Called “Impressive”

This article is from The Cancer Letter archive.

Vol. 21 No. 03 | January 20, 1995

Download PDF Visit The Full Archive

Related Articles

Editorial: A Record-Breaking Year for The Cancer Letter

December 19, 2014

Novartis Submits Gleevec Data To FDA Seeking Approval For Use In GI Tumors.

October 26, 2001

Rhoads Presses For Greater Emphasis On Etiology In DNCP; Workshops Develop New Research Leads

July 16, 1976

House Members Who Voted for Veto

January 3, 1986

Scientists Falsified Research, ORI Says

July 5, 1996

NCI Contract Awards.

February 18, 2000